A double-blind trial of synthetic salmon calcitonin in the treatment of acute pancreatitis.
A multicenter randomized double-blind trial on the use of synthetic salmon calcitonin (SCT) was carried out in 94 patients with acute pancreatitis. In addition to strict standard treatment--without aprotinin, atropine, or antacids--50 patients received daily 3 x 20 micrograms = 300 MRCU SCT intravenously and 44 patients received placebo for 6 days. Mortality rate was not influenced, overall mortality being 5.3%. The number of patients without pain and with normalized serum amylase on a given day was significantly higher in the group treated with SCT. Other parameters such as doses of analgesics, leukocyte count, and normalization of seven defined clinical and laboratory criteria within 6 days showed a positive trend without reaching significance.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000681:Amylases / Q000097:blood; D000700:Analgesics / Q000627:therapeutic use; D000818:Animals; D002116:Calcitonin / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology; D010919:Placebos; D011446:Prospective Studies; D011897:Random Allocation; D012474:Salmon
D000700:Analgesics; D010919:Placebos; D002116:Calcitonin; D000681:Amylases